Live Breaking News & Updates on Receptor Negative

Stay updated with breaking news from Receptor negative. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Truqap recommended for EU breast cancer approval | Company Announcement

Investegate announcements from Truqap recommended for EU breast cancer approval ....

United Kingdom , Daiichi Sankyo , Adrian Kemp , Astrazeneca Truqap , Merck Co Inc , Committee For Medicinal Products Human Use , National Cancer Institute , End Results Program , Institute Of Cancer Research , European Medicines Agency , World Health Organization , Investor Relations Team , Cancer Research Technology , European Union , National Comprehensive Cancer Network , Zeneca Truqap , Medicinal Products , Human Use , New England Journal , Astex Therapeutics , Cancer Research , Cancer Research Technology Limited , Rare Diseases , Hormone Receptor Positive Advanced Breast Cancer , World Health , Accessed April ,

Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or . ....

United Kingdom , Astrazeneca Truqap , Daiichi Sankyo , Cancer Research Technology , Committee For Medicinal Products Human Use , World Health Organization , Investor Relations Team , National Comprehensive Cancer Network , European Medicines Agency , Institute Of Cancer Research , Merck Co Inc , European Union , National Cancer Institute , End Results Program , Medicinal Products , Human Use , New England Journal , Astex Therapeutics , Cancer Research , Cancer Research Technology Limited , Rare Diseases , Hormone Receptor , Positive Advanced Breast , Accessed April , End Results , Receptor Negative ,